-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Entering the end of the year, public fund research activities are still frequent.
According to the announcements of listed companies, fund companies have investigated more than 209 listed companies since December.
Among them, biomedicine is still the "good heart" of fund companies
.
Among the over 200 companies, 45 have received intensive research from more than 10 fund companies, of which 7 are healthcare and pharmaceutical companies
.
Medical biology is still favored by fund companies.
For example, since December, China Guangfa Fund has investigated 42 listed companies, mainly in the medical biology and machinery and equipment industries, and 5 companies have been investigated
.
Since December, E Fund has surveyed 39 A-share companies, of which the main companies surveyed are companies in the electronics and medical and biological industries
.
Tianhong Fund has investigated 29 companies, of which 7 are pharmaceutical companies
.
In addition, the companies that Harvest Fund has investigated since December are also mainly in the pharmaceutical and biological, mechanical equipment, and electronics industries
.
A number of stocks have received more than 40 institutional surveys.
According to Flush Data, among the top pharmaceutical and biological companies that have received fund company surveys since December, Haier Biosciences ranks first with 51 surveys.
The stock has increased 42.
77% year-to-date.
, The current market value is 29.
443 billion yuan
.
On December 9, Haier Biotechnology issued an announcement stating that AIHC Capital, Oakwise Capital, Rays Capital, Tiger Pacific Capital LP, WT Asset Management Limited, China Securities, CITIC Securities, CITIC Securities Asset Management, Bank of China Asset Management, Zhonggang Capital 148 institutions including Chongqing Boyong Investment and Chongqing Nuoding Asset Management will investigate the company on December 7, 2021
.
Judging from the main content of this survey, the organization mainly focuses on the company's business conditions, the layout and development of new products in recent laboratories, and the development of overseas markets
.
Next is the new industry, which has received 47 surveys since December.
The stock has gained -31.
69% year-to-date, and its current market value is 37.
052 billion yuan.
.
Among them, only from December 1st to December 7th, the number of institutions participating in the new industry research reached 169, and then from December 6th to December 10th, 2021, a total of 5 institutions participated in the research
.
The organization is mainly concerned about the impact of "Anhui Centralized Procurement" on the company's operations
.
According to the company, the scope of implementation of the “Anhui Collective Procurement” mainly includes 23 reagent items including tumor markers, thyroid, infectious diseases, myocardial markers, and procalcitonin
.
The company's 14 reagent projects including tumor markers and thyroid were shortlisted to participate in the bargaining, and all negotiations were successful
.
At the same time, 8 reagent projects including the five hepatitis B and BNP that were not shortlisted for negotiation have successfully completed the linkage price reduction
.
Therefore, the company's existing 22 reagent projects can continue to be sold in Anhui Province
.
At the same time, said that at present, the company's revenue in Anhui Province still has a large gap compared with foreign brands, and the stock of small and medium-sized equipment accounts for a relatively high proportion
.
As a bid-winning manufacturer, the company will take this opportunity to actively promote the entry of the high-speed MAGLUMI X8 into more large hospitals above Class A, thereby driving the increase in reagent sales revenue
.
With the implementation of the policy, the "Anhui Central Purchasing" incident is conducive to the increase of the company's local installed capacity and has a positive impact on operating performance
.
Once again for International Medicine, 41 surveys have been obtained.
The stock price of International Medicine has increased by -5.
09% year-to-date, and its current market value is 27.
152 billion yuan
.
Among them, the Investor Relations Activity Record Form issued by International Medicine on December 10 shows that the company accepted investigations from 179 institutions on December 9, 2021.
According to the main content of investor relations activities, the institutions mainly focus on the company’s three major medical hospitals.
The business situation of Miaoyou Medical Alliance, the impact on the company’s future development after joining Miaoyou Medical Alliance, and the situation of medical beauty projects and assisted reproductive projects
.
According to the announcements of listed companies, fund companies have investigated more than 209 listed companies since December.
Among them, biomedicine is still the "good heart" of fund companies
.
Among the over 200 companies, 45 have received intensive research from more than 10 fund companies, of which 7 are healthcare and pharmaceutical companies
.
Medical biology is still favored by fund companies.
For example, since December, China Guangfa Fund has investigated 42 listed companies, mainly in the medical biology and machinery and equipment industries, and 5 companies have been investigated
.
Since December, E Fund has surveyed 39 A-share companies, of which the main companies surveyed are companies in the electronics and medical and biological industries
.
Tianhong Fund has investigated 29 companies, of which 7 are pharmaceutical companies
.
In addition, the companies that Harvest Fund has investigated since December are also mainly in the pharmaceutical and biological, mechanical equipment, and electronics industries
.
A number of stocks have received more than 40 institutional surveys.
According to Flush Data, among the top pharmaceutical and biological companies that have received fund company surveys since December, Haier Biosciences ranks first with 51 surveys.
The stock has increased 42.
77% year-to-date.
, The current market value is 29.
443 billion yuan
.
On December 9, Haier Biotechnology issued an announcement stating that AIHC Capital, Oakwise Capital, Rays Capital, Tiger Pacific Capital LP, WT Asset Management Limited, China Securities, CITIC Securities, CITIC Securities Asset Management, Bank of China Asset Management, Zhonggang Capital 148 institutions including Chongqing Boyong Investment and Chongqing Nuoding Asset Management will investigate the company on December 7, 2021
.
Judging from the main content of this survey, the organization mainly focuses on the company's business conditions, the layout and development of new products in recent laboratories, and the development of overseas markets
.
Next is the new industry, which has received 47 surveys since December.
The stock has gained -31.
69% year-to-date, and its current market value is 37.
052 billion yuan.
.
Among them, only from December 1st to December 7th, the number of institutions participating in the new industry research reached 169, and then from December 6th to December 10th, 2021, a total of 5 institutions participated in the research
.
The organization is mainly concerned about the impact of "Anhui Centralized Procurement" on the company's operations
.
According to the company, the scope of implementation of the “Anhui Collective Procurement” mainly includes 23 reagent items including tumor markers, thyroid, infectious diseases, myocardial markers, and procalcitonin
.
The company's 14 reagent projects including tumor markers and thyroid were shortlisted to participate in the bargaining, and all negotiations were successful
.
At the same time, 8 reagent projects including the five hepatitis B and BNP that were not shortlisted for negotiation have successfully completed the linkage price reduction
.
Therefore, the company's existing 22 reagent projects can continue to be sold in Anhui Province
.
At the same time, said that at present, the company's revenue in Anhui Province still has a large gap compared with foreign brands, and the stock of small and medium-sized equipment accounts for a relatively high proportion
.
As a bid-winning manufacturer, the company will take this opportunity to actively promote the entry of the high-speed MAGLUMI X8 into more large hospitals above Class A, thereby driving the increase in reagent sales revenue
.
With the implementation of the policy, the "Anhui Central Purchasing" incident is conducive to the increase of the company's local installed capacity and has a positive impact on operating performance
.
Once again for International Medicine, 41 surveys have been obtained.
The stock price of International Medicine has increased by -5.
09% year-to-date, and its current market value is 27.
152 billion yuan
.
Among them, the Investor Relations Activity Record Form issued by International Medicine on December 10 shows that the company accepted investigations from 179 institutions on December 9, 2021.
According to the main content of investor relations activities, the institutions mainly focus on the company’s three major medical hospitals.
The business situation of Miaoyou Medical Alliance, the impact on the company’s future development after joining Miaoyou Medical Alliance, and the situation of medical beauty projects and assisted reproductive projects
.
